308. Biodyne USA’s Bodie Kitchel on the economics of biologicals, the pursuit of answers + innovating with urgency

This is a podcast episode titled, 308. Biodyne USA’s Bodie Kitchel on the economics of biologicals, the pursuit of answers + innovating with urgency. The summary for this episode is: <p>Biologicals – the broad category of ag input products derived from living organisms – have experienced significant growth in terms of adoption and investment. An analysis of Pitchbook data reveals there have been more than 6,000 deals in the global ag biotech market over the past decade. One of those companies driving growth is Biodyne USA. This week, we are joined by their National Director of Agronomy, Bodie Kitchel, to talk Biologicals vs. Biostimulants and what’s driving growth in the space.&nbsp;</p><p><br></p><p>For Bodie, everyone’s “why” looks a little different when it comes to the adoption of biologicals and farm economics are certainly a piece of that. He gets into the farmer mindset around adopting innovation to leverage net farm income and Biodyne being an education company to help farmers learn where their dollar has the most value. Bodie also talks about needing economic impact right away but also balancing that belief with the value of economic impact in years two, three, four and five.&nbsp;</p><p><br></p><p>With his experience in ag retail, how has Bodie seen innovation evolve? He talks about positioning, investment and companies being afraid of the unknown. Looking ahead, Bodie talks about that fear being outweighed by the urgency around innovating – and Biodyne USA doing it with speed.&nbsp;</p>